【 文献重点摘要 】
 

To characterize satisfaction with current standard-of-care botulinum neurotoxin type A (BoNT/A) treatment for blepharospasm, we performed a cross-sectional, structured survey in subjects with blepharospasm who had received ≥2 BoNT/A cycles. Subjects were interviewed immediately before re-injection to evaluate treatment satisfaction, time course of treatment effects, preferred injection intervals, Jankovic Rating Scale (JRS), and Blepharospasm Disability Index (BSDI).

Subjects’ (n = 114) last treatment was onabotulinumtoxinA (n = 78), incobotulinumtoxinA (n = 35 ) , or abobotulinumtoxinA (n = 1). The most frequent injection interval was 12 weeks (46.5% subjects); 30.7% had an interval>12 weeks. The main rationale for interval choice was “to maintain treatment efficacy” (44.7%). However, 36.6% reported that treatment effects usually declined within 8 weeks; 69.6% within 10 weeks. JRS and BSDI scores indicated re-emergence of symptoms before re-injection, with 70.2% and 73.7% of subjects reporting difficulties to drive and read, respectively. Overall, treatment satisfaction was high, but declined at the end of the cycle. Many subjects (52.3%) would prefer an injection interval of <12 weeks; 30.6% of <10 weeks. In conclusion, the survey results indicate that blepharospasm symptoms, such as difficulties to drive and read, reemerge at the end of a BoNT treatment cycle and that flexible, individualized treatment intervals may improve treatment satisfaction and outcomes.

为了表征目前A型肉毒神经毒素(BoNT/A)治疗眼睑痉挛的满意度，我们对接受了≥2 BoNT/A周期的眼睑痉挛受试者进行了一项横断面、结构化的调查。在再次注射前立即对受试者进行访谈，以评估治疗满意度、疗程效果、首选注射间隔、Jankovic评定量表(JRS)和眼睑痉挛残疾指数(BSDI)。

最后一次治疗的受试者(n=114)为onabotulinumtoxinA组(78例)、incobotulinumtoxinA组(35例)和abobotulinumtoxinA组(1例)。注射间隔最频繁的是12周(46.5%)，30.7%的注射间隔>12周。选择间隔的主要理由是“维持治疗效果”(44.7%)。然而，36.6%的人报告治疗效果通常在8周内下降，69.6%的人在10周内下降。JRS和BSDI评分显示再次注射前症状再次出现，分别有70.2%和73.7%的受试者报告驾驶和阅读困难。总体而言，治疗满意度很高，但在周期结束时有所下降。许多受试者(52.3%)希望注射间隔<12周；30.6%的受试者希望注射间隔<10周。总之，调查结果表明，眼睑痉挛症状，如驾驶和阅读困难，在BoNT治疗周期结束时再次出现，灵活的、个性化的治疗间隔可能会提高治疗满意度和结果。